Department of Pediatrics, University of Massachusetts Medical School, 373 Plantation Street, Suite 318, Worcester 01605, MA, USA.
Infect Agent Cancer. 2013 Sep 30;8(1):36. doi: 10.1186/1750-9378-8-36.
Survival rates for children diagnosed with Burkitt lymphoma (BL) in Africa are far below those achieved in developed countries. Late stage of presentation contributes to poor prognosis, therefore this study investigated factors leading to delays in BL diagnosis and treatment of children in Uganda and western Kenya.
Guardians of children diagnosed with BL were interviewed at the Jaramogi Oginga Odinga Teaching and Referral Hospital (JTRH) and Uganda Cancer Institute (UCI) from Jan-Dec 2010. Information on sociodemographics, knowledge, attitudes, illness perceptions, health-seeking behaviors and prior health encounters was collected using a standardized, pre-tested questionnaire.
Eighty-two guardians were interviewed (20 JTRH, 62 UCI). Median "total delay" (1st symptoms to BL diagnosis) was 12.1 weeks [interquartile range (IQR) 4.9-19.9] in Kenya and 12.9 weeks (IQR 4.3-25.7) in Uganda. In Kenya, median "guardian delay" (1st symptoms to 1st health encounter) and "health system delay" (1st health encounter to BL diagnosis) were 9.0 weeks (IQR 3.6-15.7) and 2.0 weeks (IQR 1.6-5.8), respectively. Data on guardian and health system delay in Uganda were only available for those with < 4 prior health encounters (n = 26). Of these, median guardian delay was 4.3 weeks (range 0.7-149.9), health system delay 2.6 weeks (range 0.1-16.0), and total delay 10.7 weeks (range 1.7-154.3). Guardians in Uganda reported more health encounters than those in Kenya (median 5, range 3-16 vs. median 3, range 2-6). Among Kenyan guardians, source of income was the only independent predictor of delay, whereas in Uganda, guardian delay was influenced by guardians' beliefs on the curability of cancer, health system delay, by guardians' perceptions of cancer as a contagious disease, and total delay, by the number of children in the household and guardians' role as caretaker. Qualitative findings suggest financial costs, transportation, and other household responsibilities were major barriers to care.
Delays from symptom onset to BL treatment were considerable given the rapid growth rate of this cancer, with guardian delay constituting the majority of total delay in both settings. Future interventions should aim to reduce structural barriers to care and increase awareness of BL in particular and cancer in general within the community, as well as among health professionals.
在非洲,被诊断患有伯基特淋巴瘤(BL)的儿童的生存率远低于发达国家。就诊时已处于晚期是导致预后不良的原因之一,因此本研究旨在调查乌干达和肯尼亚西部导致 BL 诊断和治疗延误的因素。
2010 年 1 月至 12 月,在乔莫·肯雅塔教学与转诊医院(JTRH)和乌干达癌症研究所(UCI)对被诊断为 BL 的儿童的监护人进行访谈。使用标准化的预测试问卷收集社会人口统计学、知识、态度、疾病认知、求医行为和之前的健康接触信息。
共访谈了 82 位监护人(20 位 JTRH,62 位 UCI)。肯尼亚的中位“总延误”(从症状出现到 BL 诊断)为 12.1 周(四分位距 [IQR] 4.9-19.9),乌干达为 12.9 周(IQR 4.3-25.7)。在肯尼亚,中位“监护人延误”(从症状出现到首次就诊)和“卫生系统延误”(首次就诊到 BL 诊断)分别为 9.0 周(IQR 3.6-15.7)和 2.0 周(IQR 1.6-5.8)。乌干达的监护人延误和卫生系统延误的数据仅适用于之前就诊次数少于 4 次的患者(n=26)。其中,中位监护人延误为 4.3 周(范围 0.7-149.9),卫生系统延误为 2.6 周(范围 0.1-16.0),总延误为 10.7 周(范围 1.7-154.3)。与肯尼亚的监护人相比,乌干达的监护人报告的就诊次数更多(中位值 5,范围 3-16 与中位值 3,范围 2-6)。在肯尼亚的监护人中,收入来源是唯一的独立延迟预测因素,而在乌干达,监护人的延迟受到监护人对癌症可治愈性的信念、卫生系统延迟、监护人对癌症的认知(传染性疾病)、总延迟的影响,受家庭中儿童数量和监护人照顾者角色的影响。定性研究结果表明,经济成本、交通和其他家庭责任是护理的主要障碍。
鉴于这种癌症的快速生长速度,从症状出现到 BL 治疗的延误时间相当长,在这两个地区,监护人的延误构成了总延误的大部分。未来的干预措施应旨在减少护理方面的结构性障碍,并提高社区,特别是卫生专业人员对 BL 和癌症的认识。